Interleukin-6 in inflammatory and malignant diseases of the pancreas

Seminars in Immunology

Volumn 26, Issue 1, 2014, Pages 80-87

  Lesina, Marina ^a   Wörmann, Sonja Maria ^a   Neuhöfer, Patrick ^a   Song, Liang ^a   Algül, Hana ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acute pancreatitis; Chronic pancreatitis; IL 6 signaling; IL 6 trans signaling; Pancreatic cancer; STAT3

Indexed keywords

INTERLEUKIN 6; JANUS KINASE; STAT PROTEIN; STAT3 PROTEIN;

ACUTE PANCREATITIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CHRONIC PANCREATITIS; DISEASE EXACERBATION; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; PANCREAS CANCER; PANCREATITIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ACUTE PANCREATITIS; CHRONIC PANCREATITIS; IL-6 SIGNALING; IL-6 TRANS-SIGNALING; PANCREATIC CANCER; STAT3;

ANIMALS; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-6; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; PANCREATITIS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR MICROENVIRONMENT;

EID: 84896493991     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2014.01.002     Document Type: Review

References (137)

1. GLOBOCAN GLOBOCAN 2008 2008, (IARC) Section of Cancer Information, (26/6/2013). http://globocan.iarc.fr/factsheets/populations/factsheet.asp%3Funo=900.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
3. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 2010, at: http://globocaniarcfr [Internet].
4. Bosetti C., Bertuccio P., Negri E., La Vecchia C., Zeegers M.P., Boffetta P. Pancreatic cancer: overview of descriptive epidemiology. Mol Carcinog 2012, 51:3-13.
5. Hariharan D., Saied A., Kocher H.M. Analysis of mortality rates for pancreatic cancer across the world. Off J Int Hepat Pancreat Biliary Assoc 2008, 10:58-62.
6. Malvezzi M., Bertuccio P., Levi F., La Vecchia C., Negri E. European cancer mortality predictions for the year 2013. Ann Oncol 2013, 24:792-800.
7. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617.
8. Bilimoria K.Y., Bentrem D.J., Ko C.Y., Ritchey J., Stewart A.K., Winchester D.P., et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 2007, 110:738-744.
9. ACS (American Cancer Society) Cancer Facts & Figures 2013 2013, American Cancer Society, Atlanta.
10. Kern S.E., Shi C., Hruban R.H. The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. J Pathol 2011, 223:295-306.
11. Maitra A., Hruban R.H. Pancreatic cancer. Annu Rev Pathol 2008, 3:157-188.
12. Cooperman A.M. Pancreatic cancer: the bigger picture. Surg Clin North Am 2001, 81:557-574.
13. Cullinan S.A., Moertel C.G., Fleming T.R., Rubin J.R., Krook J.E., Everson L.K., et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. J Am Med Assoc 1985, 253:2061-2067.
14. Ni X., Yang J., Li M. Imaging-guided curative surgical resection of pancreatic cancer in a xenograft mouse model. Cancer Lett 2012, 324:179-185.
15. Stathis A., Moore M.J. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010, 7:163-172.
16. Cubilla A.L., Fitzgerald P.J. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 1976, 36:2690-2698.
17. Klimstra D.S., Longnecker D.S. K-ras mutations in pancreatic ductal proliferative lesions. Am J Pathol 1994, 145:1547-1550.
18. Kozuka S., Sassa R., Taki T., Masamoto K., Nagasawa S., Saga S., et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer 1979, 43:1418-1428.
19. Hruban R.H., Takaori K., Klimstra D.S., Adsay N.V., Albores-Saavedra J., Biankin A.V., et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004, 28:977-987.
20. Perez-Mancera P.A., Guerra C., Barbacid M., Tuveson D.A. What we have learned about pancreatic cancer from mouse models. Gastroenterology 2012, 142:1079-1092.
21. McCleary-Wheeler A.L., Lomberk G.A., Weiss F.U., Schneider G., Fabbri M., Poshusta T.L., et al. Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. Cancer Lett 2013, 328:212-221.
22. Hingorani S.R., Petricoin E.F., Maitra A., Rajapakse V., King C., Jacobetz M.A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4:437-450.
23. Hruban R.H., Goggins M., Parsons J., Kern S.E. Progression model for pancreatic cancer. Clinical Cancer Res 2000, 6:2969-2972.
24. Greer J.B., Whitcomb D.C. Inflammation and pancreatic cancer: an evidence-based review. Curr Opin Pharmacol 2009, 9:411-418.
25. Whitcomb D.C., Inflammation, Cancer V. Chronic pancreatitis and pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2004, 287:G315-G319.
26. Jura N., Archer H., Bar-Sagi D. Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between. Cell Res 2005, 15:72-77.
27. Algul H., Treiber M., Lesina M., Schmid R.M. Mechanisms of disease: chronic inflammation and cancer in the pancreas--a potential role for pancreatic stellate cells?. Nat Clin Pract Gastroenterol Hepatol 2007, 4:454-462.
28. Clark C.E., Beatty G.L., Vonderheide R.H. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett 2009, 279:1-7.
29. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
30. Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7:469-483.
31. Bayne L.J., Beatty G.L., Jhala N., Clark C.E., Rhim A.D., Stanger B.Z., et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012, 21:822-835.
32. Dodson L.F., Hawkins W.G., Goedegebuure P. Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy 2011, 3:517-537.
33. Koido S., Homma S., Takahara A., Namiki Y., Tsukinaga S., Mitobe J., et al. Current immunotherapeutic approaches in pancreatic cancer. Clin Dev Immunol 2011, 2011:267539.
34. Michl P., Gress T.M. Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid. Gut 2012, 61:1377-1379.
35. Neesse A., Michl P., Frese K.K., Feig C., Cook N., Jacobetz M.A., et al. Stromal biology and therapy in pancreatic cancer. Gut 2011, 60:861-868.
36. Clark C.E., Hingorani S.R., Mick R., Combs C., Tuveson D.A., Vonderheide R.H. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007, 67:9518-9527.
37. Chu G.C., Kimmelman A.C., Hezel A.F., DePinho R.A. Stromal biology of pancreatic cancer. J Cell Biochem 2007, 101:887-907.
38. Kleeff J., Beckhove P., Esposito I., Herzig S., Huber P.E., Lohr J.M., et al. Pancreatic cancer microenvironment. Int J Cancer 2007, 121:699-705.
39. Kubuschok B., Neumann F., Breit R., Sester M., Schormann C., Wagner C., et al. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin Cancer Res 2006, 12:1365-1372.
40. Pylayeva-Gupta Y., Lee K.E., Hajdu C.H., Miller G., Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 2012, 21:836-847.
41. Protti M.P., De Monte L. Cross-talk within the tumor microenvironment mediates Th2-type inflammation in pancreatic cancer. Oncoimmunology 2012, 1:89-91.
42. Tassi E., Braga M., Longhi R., Gavazzi F., Parmiani G., Di Carlo V., et al. Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients. PLoS ONE 2009, 4:e7234.
43. De Monte L., Reni M., Tassi E., Clavenna D., Papa I., Recalde H., et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011, 208:469-478.
44. Sundararaj K.P., Samuvel D.J., Li Y., Sanders J.J., Lopes-Virella M.F., Huang Y. Interleukin-6 released from fibroblasts is essential for up-regulation of matrix metalloproteinase-1 expression by U937 macrophages in coculture: cross-talking between fibroblasts and U937 macrophages exposed to high glucose. J Biol Chem 2009, 284:13714-13724.
45. Chi L., Li Y., Stehno-Bittel L., Gao J., Morrison D.C., Stechschulte D.J., et al. Interleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor-alpha. J Interferon Cytok Res 2001, 21:231-240.
46. Podor T.J., Jirik F.R., Loskutoff D.J., Carson D.A., Lotz M. Human endothelial cells produce IL-6. Lack of responses to exogenous IL-6. Ann N Y Acad Sci 1989, 557:377-386. 374-385; discussion.
47. Li Y.Y., Hsieh L.L., Tang R.P., Liao S.K., Yeh K.Y., Interleukin-6 (IL-6) released by macrophages induces IL-6 secretion in the human colon cancer HT-29 cell line. Hum Immunol 2009, 70:151-158.
48. Lutz H.H., Sackett S.D., Kroy D.C., Gassler N., Trautwein C. Deletion of gp130 in myeloid cells modulates IL-6-release and is associated with more severe liver injury of Con A hepatitis. Eur J Cell Biol 2012, 91:576-581.
49. Lesina M., Kurkowski M.U., Ludes K., Rose-John S., Treiber M., Kloppel G., et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011, 19:456-469.
50. Masui T., Hosotani R., Doi R., Miyamoto Y., Tsuji S., Nakajima S., et al. Expression of IL-6 receptor in pancreatic cancer: involvement in VEGF induction. Anticancer Res 2002, 22:4093-4100.
51. Feurino L.W., Zhang Y., Bharadwaj U., Zhang R., Li F., Fisher W.E., et al. IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells. Cancer Biol Ther 2007, 6:1096-1100.
52. Ebrahimi B., Tucker S.L., Li D., Abbruzzese J.L., Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 2004, 101:2727-2736.
53. Miyamoto Y., Hosotani R., Doi R., Wada M., Ida J., Tsuji S., et al. Interleukin-6 inhibits radiation induced apoptosis in pancreatic cancer cells. Anticancer Res 2001, 21:2449-2456.
54. Fukuda A., Wang S.C., Morris JPt, Folias A.E., Liou A., Kim G.E., et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011, 19:441-455.
55. Okada S., Okusaka T., Ishii H., Kyogoku A., Yoshimori M., Kajimura N., et al. Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol 1998, 28:12-15.
56. Barber M.D., Fearon K.C., Ross J.A. Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer. Clin Sci (Lond) 1999, 96:83-87.
57. Moses A.G., Maingay J., Sangster K., Fearon K.C., Ross J.A. Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol Rep 2009, 21:1091-1095.
58. Mroczko B., Groblewska M., Gryko M., Kedra B., Szmitkowski M. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal 2010, 24:256-261.
59. Wigmore S.J., Fearon K.C., Sangster K., Maingay J.P., Garden O.J., Ross J.A. Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol 2002, 21:881-886.
60. Martignoni M.E., Kunze P., Hildebrandt W., Kunzli B., Berberat P., Giese T., et al. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res 2005, 11:5802-5808.
61. Bellone G., Smirne C., Mauri F.A., Tonel E., Carbone A., Buffolino A., et al. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 2006, 55:684-698.
62. Mayr M., Schmid R.M. Pancreatic cancer and depression: myth and truth. BMC Cancer 2010, 10:569.
63. Michalaki V., Syrigos K., Charles P., Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004, 90:2312-2316.
64. Berek J.S., Chung C., Kaldi K., Watson J.M., Knox R.M., Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1991, 164:1038-1042. discussion 1042-1033.
65. Ueda T., Shimada E., Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 1994, 29:423-429.
66. Zhang D., Zhou Y., Wu L., Wang S., Zheng H., Yu B., et al. Association of IL-6 gene polymorphisms with cachexia susceptibility and survival time of patients with pancreatic cancer. Ann Clin Lab Sci 2008, 38:113-119.
67. Talar-Wojnarowska R., Gasiorowska A., Smolarz B., Romanowicz-Makowska H., Kulig A., Malecka-Panas E. Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci 2009, 54:683-689.
68. Saito K., Ishikura H., Kishimoto T., Kawarada Y., Yano T., Takahashi T., et al. Interleukin-6 produced by pancreatic carcinoma cells enhances humoral immune responses against tumor cells: a possible event in tumor regression. Int J Cancer 1998, 75:284-289.
69. Tang R.F., Wang S.X., Zhang F.R., Peng L., Wang S.X., Xiao Y., et al. Interleukin-1alpha, 6 regulate the secretion of vascular endothelial growth factor A, C in pancreatic cancer. Hepatobiliary Pancreat Dis Int 2005, 4:460-463.
70. Ancrile B., Lim K.H., Counter C.M. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007, 21:1714-1719.
71. Kang R., Loux T., Tang D., Schapiro N.E., Vernon P., Livesey K.M., et al. The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A 2012, 109:7031-7036.
72. Zhang Y., Yan W., Collins M.A., Bednar F., Rakshit S., Zetter B.R., et al. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res 2013, 73:6359-6374.
73. Lee H., Deng J., Kujawski M., Yang C., Liu Y., Herrmann A., et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 2010, 16:1421-1428.
74. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809.
75. Adam N., Rabe B., Suthaus J., Grotzinger J., Rose-John S., Scheller J. Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor. J Virol 2009, 83:5117-5126.
76. Huang C., Yang G., Jiang T., Huang K., Cao J., Qiu Z. Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro. J Exp Clin Cancer Res 2010, 29:51.
77. Toyonaga T., Nakano K., Nagano M., Zhao G., Yamaguchi K., Kuroki S., et al. Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett 2003, 201:107-116.
78. Liu A., Liu Y., Li P.K., Li C., Lin J. LLL12 inhibits endogenous and exogenous interleukin-6-induced STAT3 phosphorylation in human pancreatic cancer cells. Anticancer Res 2011, 31:2029-2035.
79. Baker A.D., Cui T., Laheru A., Campen D., Von Hoff C., Hidalgo D.D. M; PCRT Investigators. Plasma IL-6 level and survival of pancreatic cancer patients treated with a VEGFR inhibitor, vatalanib (PTK/ZK). J Clin Oncol 2009, 27.
80. Trikha M., Corringham R., Klein B., Rossi J.F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003, 9:4653-4665.
81. Jones S.A., Scheller J., Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Investig 2011, 121:3375-3383.
82. Whitcomb D.C. Clinical practice. Acute pancreatitis. N Engl J Med 2006, 354:2142-2150.
83. Bhatia M. Acute pancreatitis as a model of SIRS. Front Biosci (Landmark Ed) 2009, 14:2042-2050.
84. Schutte K., Malfertheiner P. Markers for predicting severity and progression of acute pancreatitis. Best Pract Res Clin Gastroenterol 2008, 22:75-90.
85. Rau B., Steinbach G., Baumgart K., Gansauge F., Grunert A., Beger H.G. Serum amyloid A versus C-reactive protein in acute pancreatitis: clinical value of an alternative acute-phase reactant. Crit Care Med 2000, 28:736-742.
86. Makhija R., Kingsnorth A.N. Cytokine storm in acute pancreatitis. J Hepatobiliary Pancreat Surg 2002, 9:401-410.
87. Papachristou G.I. Prediction of severe acute pancreatitis: current knowledge and novel insights. World J Gastroenterol 2008, 14:6273-6275.
88. Bhatia M., Brady M., Shokuhi S., Christmas S., Neoptolemos J.P., Slavin J. Inflammatory mediators in acute pancreatitis. J Pathol 2000, 190:117-125.
89. Leser H.G., Gross V., Scheibenbogen C., Heinisch A., Salm R., Lausen M., et al. Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology 1991, 101:782-785.
90. Viedma J.A., Perez-Mateo M., Dominguez J.E., Carballo F. Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A. Gut 1992, 33:1264-1267.
91. Dugernier T.L., Laterre P.F., Wittebole X., Roeseler J., Latinne D., Reynaert M.S., et al. Compartmentalization of the inflammatory response during acute pancreatitis: correlation with local and systemic complications. Am J Respir Crit Care Med 2003, 168:148-157.
92. Mayer J., Rau B., Gansauge F., Beger H.G. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut 2000, 47:546-552.
93. Brivet F.G., Emilie D., Galanaud P. Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. Parisian Study Group on Acute Pancreatitis. Crit Care Med 1999, 27:749-755.
94. Novovic S., Andersen A.M., Ersboll A.K., Nielsen O.H., Jorgensen L.N., Hansen M.B. Proinflammatory cytokines in alcohol or gallstone induced acute pancreatitis. A prospective study. J Pancreas 2009, 10:256-262.
95. Malmstrom M.L., Hansen M.B., Andersen A.M., Ersboll A.K., Nielsen O.H., Jorgensen L.N., et al. Cytokines and organ failure in acute pancreatitis: inflammatory response in acute pancreatitis. Pancreas 2012, 41:271-277.
96. Ley E.J., Clond M.A., Singer M.B., Shouhed D., Salim A. IL6 deficiency affects function after traumatic brain injury. J Surg Res 2011, 170:253-256.
97. Matthews V.B., Allen T.L., Risis S., Chan M.H., Henstridge D.C., Watson N., et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 2010, 53:2431-2441.
98. Wu W., Clark E.A., Stoddard G.J., Watkins W.S., Esplin M.S., Manuck T.A., et al. Effect of interleukin-6 polymorphism on risk of preterm birth within population strata: a meta-analysis. BMC Genet 2013, 14:30.
99. Martinez A.N., Mehra S., Kaushal D. Role of interleukin 6 in innate immunity to Mycobacterium tuberculosis infection. J Infect Dis 2013, 207:1253-1261.
100. Chao K.C., Chao K.F., Chuang C.C., Liu S.H. Blockade of interleukin 6 accelerates acinar cell apoptosis and attenuates experimental acute pancreatitis in vivo. Br J Surg 2006, 93:332-338.
101. Suzuki S., Miyasaka K., Jimi A., Funakoshi A. Induction of acute pancreatitis by cerulein in human IL-6 gene transgenic mice. Pancreas 2000, 21:86-92.
102. Zhang H., Neuhofer P., Song L., Rabe B., Lesina M., Kurkowski M.U., et al. IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality. J Clin Investig 2013, 123:1019-1031.
103. Su K.H., Cuthbertson C., Christophi C. Review of experimental animal models of acute pancreatitis. Off J Int Hepat Pancreat Biliary Assoc 2006, 8:264-286.
104. Elder A.S., Saccone G.T., Dixon D.L. Lung injury in acute pancreatitis: mechanisms underlying augmented secondary injury. Pancreatology 2012, 12:49-56.
105. Lampel M., Kern H.F. Acute interstitial pancreatitis in the rat induced by excessive doses of a pancreatic secretagogue. Virch Archiv A Pathol Anat Histol 1977, 373:97-117.
106. Watanabe O., Baccino F.M., Steer M.L., Meldolesi J. Supramaximal caerulein stimulation and ultrastructure of rat pancreatic acinar cell: early morphological changes during development of experimental pancreatitis. Am J Physiol 1984, 246:G457-G467.
107. Niederau C., Ferrell L.D., Grendell J.H. Caerulein-induced acute necrotizing pancreatitis in mice: protective effects of proglumide, benzotript, and secretin. Gastroenterology 1985, 88:1192-1204.
108. Renner I.G., Wisner J.R. Ceruletide-induced acute pancreatitis in the dog and its amelioration by exogenous secretin. Int J Pancreatol 1986, 1:39-49.
109. Rinderknecht H. Fatal pancreatitis, a consequence of excessive leukocyte stimulation?. Int J Pancreatol 1988, 3:105-112.
110. Dominguez-Munoz J.E., Carballo F., Garcia M.J., Miguel de Diego J., Gea F., Yanguela J., et al. Monitoring of serum proteinase-antiproteinase balance and systemic inflammatory response in prognostic evaluation of acute pancreatitis. Results of a prospective multicenter study. Digest Dis Sci 1993, 38:507-513.
111. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989, 169:333-338.
112. Park E.J., Lee J.H., Yu G.Y., He G., Ali S.R., Holzer R.G., et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
113. Guice K.S., Oldham K.T., Johnson K.J., Kunkel R.G., Morganroth M.L., Ward P.A. Pancreatitis-induced acute lung injury. An ARDS model. Ann Surg 1988, 208:71-77.
114. Algul H., Treiber M., Lesina M., Nakhai H., Saur D., Geisler F., et al. Pancreas-specific RelA/p65 truncation increases susceptibility of acini to inflammation-associated cell death following cerulein pancreatitis. J Clin Investig 2007, 117:1490-1501.
115. Neuhofer P., Liang S., Einwachter H., Schwerdtfeger C., Wartmann T., Treiber M., et al. Deletion of IkappaBalpha activates RelA to reduce acute pancreatitis in mice through up-regulation of Spi2A. Gastroenterology 2013, 144:192-201.
116. Cuzzocrea S., Mazzon E., Dugo L., Centorrino T., Ciccolo A., McDonald M.C., et al. Absence of endogenous interleukin-6 enhances the inflammatory response during acute pancreatitis induced by cerulein in mice. Cytokine 2002, 18:274-285.
117. Kang M., Park K.S., Seo J.Y., Kim H. Lycopene inhibits IL-6 expression in cerulein-stimulated pancreatic acinar cells. Genes Nutr 2011, 6:117-123.
118. Lee J. Hwan Kim K, Kim H. Role of vascular endothelial growth factor-D (VEGF-D) on IL-6 expression in cerulein-stimulated pancreatic acinar cells. Ann N Y Acad Sci 2007, 1095:129-133.
119. Yu J.H., Kim K.H., Kim H. SOCS 3 and PPAR-gamma ligands inhibit the expression of IL-6 and TGF-beta1 by regulating JAK2/STAT3 signaling in pancreas. Int J Biochem Cell Biol 2008, 40:677-688.
120. Rabe B., Chalaris A., May U., Waetzig G.H., Seegert D., Williams A.S., et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008, 111:1021-1028.
121. Mullberg J., Schooltink H., Stoyan T., Gunther M., Graeve L., Buse G., et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 1993, 23:473-480.
122. Lust J.A., Donovan K.A., Kline M.P., Greipp P.R., Kyle R.A., Maihle N.J. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 1992, 4:96-100.
123. Chalaris A., Gewiese J., Paliga K., Fleig L., Schneede A., Krieger K., et al. ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by gamma-secretase. Biochim Biophys Acta 2010, 1803:234-245.
124. Chalaris A., Rabe B., Paliga K., Lange H., Laskay T., Fielding C.A., et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 2007, 110:1748-1755.
125. Matthews V., Schuster B., Schutze S., Bussmeyer I., Ludwig A., Hundhausen C., et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 2003, 278:38829-38839.
126. McFarland-Mancini M.M., Funk H.M., Paluch A.M., Zhou M., Giridhar P.V., Mercer C.A., et al. Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J Immunol 2010, 184:7219-7228.
127. Witt H., Apte M.V., Keim V., Wilson J.S. Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy. Gastroenterology 2007, 132:1557-1573.
128. Witt H. Chronic pancreatitis and cystic fibrosis. Gut 2003, 52(Suppl 2):ii31-ii41.
129. Ammann R.W., Buehler H., Muench R., Freiburghaus A.W., Siegenthaler W. Differences in the natural history of idiopathic (nonalcoholic) and alcoholic chronic pancreatitis. A comparative long-term study of 287 patients. Pancreas 1987, 2:368-377.
130. Durbec J.P., Sarles H. Multicenter survey of the etiology of pancreatic diseases. Relationship between the relative risk of developing chronic pancreaitis and alcohol, protein and lipid consumption. Digestion 1978, 18:337-350.
131. Bendicho M.T., Guedes J.C., Silva N.N., Santana G.O., dos Santos R.R., Lyra A.C., et al. Polymorphism of cytokine genes (TGF-beta1, IFN-gamma, IL-6, IL-10, and TNF-alpha) in patients with chronic pancreatitis. Pancreas 2005, 30:333-336.
132. Howell W.M., Pead P.J., Shek F.W., Rose-Zerilli M.J., Armstrong T., Johnson C.D., et al. Influence of cytokine and ICAM-1 gene polymorphisms on susceptibility to chronic pancreatitis. J Clin Pathol 2005, 58:595-599.
133. Apte M.V., Wilson J.S. Mechanisms of pancreatic fibrosis. Dig Dis 2004, 22:273-279.
134. Mair M., Blaas L., Osterreicher C.H., Casanova E., Eferl R. JAK-STAT signaling in hepatic fibrosis. Front Biosci (Landmark Ed) 2011, 16:2794-2811.
135. Knight D., Mutsaers S.E., Prele C.M. STAT3 in tissue fibrosis: is there a role in the lung?. Pulmon Pharmacol Ther 2011, 24:193-198.
136. Mews P., Phillips P., Fahmy R., Korsten M., Pirola R., Wilson J., et al. Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis. Gut 2002, 50:535-541.
137. Guerra C., Collado M., Navas C., Schuhmacher A.J., Hernandez-Porras I., Canamero M., et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 2011, 19:728-739.